RCS - Moderna Inc - Chantal Friebertshäuser Joins Moderna

ModernaAnnouncement

20/12/2022 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221220:nRST3543Ka&default-theme=true

RNS Number : 3543K  Moderna Inc  20 December 2022

Chantal Friebertshäuser Joins Moderna as Senior Vice President, Commercial

Newly created role will have responsibility for commercial efforts in Europe,
Middle East and Canada

CAMBRIDGE, MA / ACCESSWIRE / December 20, 2022 / Moderna, Inc
(https://pr.report/HepGIT5V) . (NASDAQ:MRNA), a biotechnology company
pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the
appointment of Chantal Friebertshäuser as Senior Vice President, Commercial,
Europe, Middle East and Canada effective January 1, 2023. Ms. Friebertshäuser
will be responsible for commercial efforts in Europe, Middle East and Canada,
reporting to Arpa Garay, Moderna's Chief Commercial Officer.

"Chantal has extensive experience in leading global teams and scaling
commercial organizations regionally," said Arpa Garay, Moderna's Chief
Commercial Officer. "Her insights, drive and commitment to patients will be
instrumental as we enter new markets and advance our platform-based approach
to medicine. Having worked with her previously, I know first-hand that she
will be a terrific addition to the organization."

Ms. Friebertshäuser joins Moderna from Merck Sharp & Dohme (MSD), where
she served in a variety of in-market and global commercial leadership roles
across 15 years, including her most recent position of Human Health Senior
Vice President and Managing Director at MSD Germany. In this role, Ms.
Friebertshäuser was responsible for the company's Human Health Organization
and also led the MSD Country Council which convened leaders from the
organization's Human Health, Animal Health, Research and Manufacturing sites.
Other prior roles include German Business Unit Leader, Global Market Access
Leader, Managing Director of Austria and Global Commercial Lead for the
company's HPV vaccine franchise. Prior to MSD, Ms. Friebertshäuser spent 10
years in various roles at Eli Lilly.

"Over the course of my career, I've always had a deep passion for bringing
forward business solutions that improve lives, while also building diverse
teams unified by a common, impactful mission," said Ms. Friebertshäuser. "I
am thrilled to join Moderna and the mission to transform medicine - and the
world - through the promise of mRNA and look forward to expanding its presence
in Europe, Middle-East and Canada."

Ms. Friebertshäuser holds a Master of Arts in International Business from the
School of Business ESC in Rennes, France. She will be based in Switzerland.

About Moderna

In over 10 years since its inception, Moderna has transformed from a
research-stage company advancing programs in the field of messenger RNA
(mRNA), to an enterprise with a diverse clinical portfolio of vaccines and
therapeutics across seven modalities, a broad intellectual property portfolio
in areas including mRNA and lipid nanoparticle formulation, and an integrated
manufacturing plant that allows for both clinical and commercial production at
scale. Moderna maintains alliances with a broad range of domestic and overseas
government and commercial collaborators. Most recently, Moderna's capabilities
have come together to allow the authorized use and approval of one of the
earliest and most effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied
mRNA science, delivery technology and manufacturing, and has allowed the
development of therapeutics and vaccines for infectious diseases,
immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune
diseases. Moderna has been named a top biopharmaceutical employer by Science
for the past eight years. To learn more, visit www.modernatx.com
(https://pr.report/Alai4TKO) .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, as amended, including
regarding: the hiring of Chantal Friebertshäuser as Senior Vice President,
Commercial, Europe, Middle East and Canada for Moderna. The forward-looking
statements in this press release are neither promises nor guarantees, and you
should not place undue reliance on these forward-looking statements because
they involve known and unknown risks, uncertainties, and other factors, many
of which are beyond Moderna's control and which could cause actual results to
differ materially from those expressed or implied by these forward-looking
statements. These risks, uncertainties, and other factors include those other
risks and uncertainties described under the heading "Risk Factors" in
Moderna's most recent Annual Report on Form 10-K and the Quarterly Report on
Form 10-Q for the quarter ended March 31, 2022, each filed with the U.S.
Securities and Exchange Commission (SEC) and in subsequent filings made by
Moderna with the SEC, which are available on the SEC's website at www.sec.gov
(https://pr.report/8yvAm2ji) . Except as required by law, Moderna disclaims
any intention or responsibility for updating or revising any forward-looking
statements contained in this press release in the event of new information,
future developments or otherwise. These forward-looking statements are based
on Moderna's current expectations and speak only as of the date of this press
release.

Moderna Contacts

Media:

Luke Mircea Willats

Director, Corporate Communications

Luke.Mirceawillats@modernatx.com

Investors:

Lavina Talukdar

Senior Vice President & Head of Investor Relations

617-209-5834

Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPPGRCPUPPGPU